Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
22 Cards in this Set
- Front
- Back
|
Mechanism:
rhuMAb-VEGF |
Bevacizumab |
|
|
Mechanism:
rh/mMAb-EGFR |
Cetuximab |
|
|
Mechanism:
Nutritional supplement; used to counterbalance deficiencies of HCl in the gastric juice |
Glutamic Acid |
|
|
Mechanism:
Oral TKI as adjuvant treatment following complete resection of Kit (CD117) positive GIST |
Imatinib |
|
|
Mechanism:
Reduced folate; synergizes with 5-FU |
Leucovorin |
|
|
Mechanism:
Serotonin inhibitor in GI tract |
Methysergide |
|
|
Mechanism:
Somatostatin analog; reduces duodenal bicarbonate, amylase, reduces gastric acidity, inhibits gallbladder contractility and bile secretion, inhibits meal-induced increases in superior mesenteric artery and portal venous blood flow |
Octreotide |
|
|
Mechanism:
Oral multi-kinase inhibitor targeting serine/threonine and receptor tyrosine kinases in both tumor and vasculature. Targeted kinases include Raf kinase, vascular endothelial growth factor (VEGF) receptors VEGFR-2 and VEGFR-3, platelet- derived growth factor receptor-β (PDGFR-β), Kit receptor tyrosine kinase (KIT), fms-like tyrosine kinase 3 (FLT-3), and RET |
Sorafenib |
|
|
Mechanism:
Inhibitor of > 80 receptor tyrosine kinases (RTKs) including PDGFRα & PDGRFβ, vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSR-1R), and the glial cell-line derived neurotrophic factor receptor (RET) |
Sunitinib |
|
|
Mechanism:
HER-2/neu antibody; HER2 is downregulated, cyclin-dependent kinase inhibitor p27 accumulates, and cell cycle arrest occurs. Also inhibits the constitutive HER2 cleavage/shedding mediated by metalloproteases, which may correlate with the clinical activity |
Trastuzumab |
|
|
Mechanism:
EGFR-TKI |
Erlotinib |
|
|
Issues:
Bleeding, GI perforation, wound dehiscence, hypertension, hypersensitivity |
Bevacizumab |
|
|
Issues:
Cardiac arrest, respiratory arrest, and/or sudden death; infusion reactions. Acneiform rash common (76-88%), severe in up to 17% of patients |
Cetuximab |
|
|
Issues:
GI toxicity (N/V, diarrhea) prolonged bleeding, elevated LFTs, ocular toxicities; rarely interstitial lung disease |
Erlotinib |
|
|
Issues:
Taken orally before meals |
Glutamic acid |
|
|
Issues:
GI toxicities (pain, bloating, N/V, constipation, stomatitis, dyspepsia, etc) common. CHF reported in some pts. Neurologic toxicity; fluid retention and edema |
Imatinib |
|
|
Issues:
Diarrhea & dehydration |
Leucovorin |
|
|
Issues:
Vasoconstrictor of large and small arteries; used for migraine therapy |
Methysergide |
|
|
Issues:
Monitor blood glucose; inhibits insulin and glucagon. Dose- related diarrhea |
Ocretotide |
|
|
Issues:
Hand-foot skin reaction characterized by redness, pain, swelling, or blisters on the palms of the hands or soles of the feet. Generally appears in first 6-weeks of treatment. |
Sorafenib |
|
|
Issues:
Thrombocytopenia and bleeding. QT prolongation, sometimes fatal, gastrointestinal (GI) complications including GI perforation have occurred rarely in patients with intraabdominal malignancies |
Suntinib |
|
|
Issues:
LVEF dysfunction and cardiomyopathy. Severe infusion-related reactions including anaphylaxis, angioedema, and pulmonary toxicity; pulmonary toxicity worse in pts with intrinsic lung disease, e.g., COPD, asthma, respiratory insufficiency |
Trastuzumab |
